PMID- 31410117
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 18
IP  - 3
DP  - 2019 Sep
TI  - Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through 
      modulation of the toll-like receptor 4/NF-kappaB signaling pathway.
PG  - 1619-1626
LID - 10.3892/etm.2019.7726 [doi]
AB  - The aim of the present study was to explore the pharmacological role of 
      rivaroxaban in rats with arteriosclerosis obliterans (ASO) and the potential 
      mechanism of its action. A total of 60 adult male Sprague Dawley (weighing 
      210-250 g) were randomly assigned into either the sham group, model group or Riv 
      group. Rats in the sham group were fed a normal diet, whereas those in model 
      group and Riv group were fed a high-fat diet for 8 weeks. After establishment of 
      the ASO model, rats in the Riv group were intragastrically administered 10 mg/kg 
      rivaroxaban, whereas those in the sham group and the model group were 
      administrated with the same volume of 0.9% saline for 4 weeks. At the end of 
      animal procedures, a blood sample and the femoral artery of the rats were 
      harvested. The results of the present study revealed that rats in the model group 
      presented with an irregularly narrowed femoral artery lumen, disordered 
      endothelial cells, internal elastic plates and smooth muscle cells. By 
      comparison, the arterial wall structure and stenosis of the femoral artery of 
      rats in Riv group recovered and all the pathological changes were alleviated 
      after rivaroxaban treatment. Levels of total cholesterol, triglycerides and 
      low-density lipoproteins decreased, whereas the level of high-density 
      lipoproteins increased in the Riv group compared with the model group. 
      Rivaroxaban treatment significantly reduced serum levels of interleukin-1, tumor 
      necrosis factor-alpha and monocyte chemoattractant protein-1 (MCP-1), and increased 
      the serum level of transforming growth factor-beta (TGF-beta). Rats in the Riv group 
      had reduced expression of toll-like receptor 4 (TLR4), NF-kappaB and MCP-1, and 
      increased expression of TGF-beta in femoral artery tissues compared with the model 
      group. Therefore rivaroxaban may have exerted its anti-atherosclerotic effects by 
      regulating the expression of genes in the TLR4/NF-kappaB signaling pathway and the 
      activation of the downstream molecules.
FAU - Lou, Xinjiang
AU  - Lou X
AD  - Department of Vascular Surgery, The Second Affiliated Hospital of Zhejiang 
      Chinese Medical University, Hangzhou, Zhejiang 310005, P.R. China.
FAU - Yu, Zhi
AU  - Yu Z
AD  - Department of Vascular Surgery, The Second Affiliated Hospital of Zhejiang 
      Chinese Medical University, Hangzhou, Zhejiang 310005, P.R. China.
FAU - Yang, Xiaoxia
AU  - Yang X
AD  - Department of Vascular Surgery, The Second Affiliated Hospital of Zhejiang 
      Chinese Medical University, Hangzhou, Zhejiang 310005, P.R. China.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Vascular Surgery, The Second Affiliated Hospital of Zhejiang 
      Chinese Medical University, Hangzhou, Zhejiang 310005, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190703
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6676094
OTO - NOTNLM
OT  - arteriosclerosis obliterans
OT  - inflammatory response
OT  - rivaroxaban
OT  - toll-like receptor 4/NF-kappaB
EDAT- 2019/08/15 06:00
MHDA- 2019/08/15 06:01
PMCR- 2019/07/03
CRDT- 2019/08/15 06:00
PHST- 2018/10/01 00:00 [received]
PHST- 2019/05/23 00:00 [accepted]
PHST- 2019/08/15 06:00 [entrez]
PHST- 2019/08/15 06:00 [pubmed]
PHST- 2019/08/15 06:01 [medline]
PHST- 2019/07/03 00:00 [pmc-release]
AID - ETM-0-0-7726 [pii]
AID - 10.3892/etm.2019.7726 [doi]
PST - ppublish
SO  - Exp Ther Med. 2019 Sep;18(3):1619-1626. doi: 10.3892/etm.2019.7726. Epub 2019 Jul 
      3.